EUVIMEDEUVIMED entdecken
Crossref

Dapagliflozin or Saxagliptin in Pediatric Type 2 Diabetes

Naim Shehadeh, Timothy Barrett, Pietro Galassetti, Cecilia Karlsson, John Monyak, Nayyar Iqbal, William V Tamborlane

NEJM Evidence · 28.11.2023 · 2 (12)

DOI: 10.1056/evidoa2300210 ↗

Kurz gefasst

Fachartikel in der Zeitschrift NEJM Evidence, erschienen am 28.11.2023. Verfasst von Naim Shehadeh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Rambam Health Care Campus, Haifa, Israel. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Dipeptides, Glucosides. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsDipeptidesGlucosidesUnited StatesAdultHumansChildHypoglycemic AgentsBenzhydryl CompoundsAdamantane

Substanzen

dapagliflozinsaxagliptinHypoglycemic AgentsBenzhydryl CompoundsSodium-Glucose Transporter 2 InhibitorsAdamantaneDipeptidesGlucosides

Autor:innen und Institutionen

  • Rambam Health Care Campus, Haifa, Israel.
  • Bar-Ilan University, Safed, Israel.
  • University of Birmingham, Birmingham, United Kingdom.
  • AstraZeneca, Gaithersburg, MD.
  • AstraZeneca, Gothenburg, Sweden.
  • Yale University, New Haven, CT.

Zitieren

APA

Shehadeh, N., Barrett, T., Galassetti, P., Karlsson, C., Monyak, J., Iqbal, N., & Tamborlane, W. V. (2023). Dapagliflozin or Saxagliptin in Pediatric Type 2 Diabetes. NEJM Evidence, 2(12). https://doi.org/10.1056/evidoa2300210

Vancouver

Shehadeh N, Barrett T, Galassetti P, Karlsson C, Monyak J, Iqbal N, et al. Dapagliflozin or Saxagliptin in Pediatric Type 2 Diabetes. NEJM Evidence. 2023;2(12). doi:10.1056/evidoa2300210

BibTeX
@article{Shehadeh2023,
  author = {Shehadeh, Naim and Barrett, Timothy and Galassetti, Pietro and Karlsson, Cecilia and Monyak, John and Iqbal, Nayyar and Tamborlane, William V},
  title = {Dapagliflozin or Saxagliptin in Pediatric Type 2 Diabetes},
  journal = {NEJM Evidence},
  year = {2023},
  volume = {2},
  number = {12},
  doi = {10.1056/evidoa2300210}
}
Kostenlos starten →